Amedisys Stock Price, News & Analysis (NASDAQ:AMED)

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last twelve months. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMED shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMED, but not buy additional shares or sell existing shares.
View AMED analyst ratings or view top-rated stocks.

11 brokers have issued 1 year target prices for Amedisys' stock. Their AMED share price targets range from $81.00 to $125.00. On average, they predict the company's stock price to reach $103.55 in the next twelve months. This suggests a possible upside of 11.3% from the stock's current price.
View analysts price targets for AMED or view top-rated stocks among Wall Street analysts.

Amedisys' stock was trading at $83.54 at the beginning of the year. Since then, AMED stock has increased by 11.4% and is now trading at $93.04.
View the best growth stocks for 2023 here.

Amedisys saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 2,470,000 shares, a drop of 5.7% from the October 31st total of 2,620,000 shares. Based on an average daily volume of 371,100 shares, the short-interest ratio is presently 6.7 days. Approximately 7.8% of the company's shares are short sold.
View Amedisys' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024.
View our AMED earnings forecast.

Amedisys, Inc. (NASDAQ:AMED) released its quarterly earnings results on Tuesday, October, 24th. The health services provider reported $0.98 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.08 by $0.10. The health services provider had revenue of $556.24 million for the quarter, compared to analysts' expectations of $560.23 million. Amedisys had a trailing twelve-month return on equity of 13.45% and a net margin of 0.12%. The firm's revenue was down .3% compared to the same quarter last year. During the same quarter last year, the firm earned $1.15 earnings per share.

ETFs with the largest weight of Amedisys (NASDAQ:AMED) stock in their portfolio include First Trust Merger Arbitrage ETF (MARB), SRH U.S. Quality ETF (SRHQ), SPDR S&P Health Care Services ETF (XHS) and IQ Merger Arbitrage ETF (MNA).iShares U.S. Healthcare Providers ETF (IHF).

478 employees have rated Amedisys Chief Executive Officer Paul B. Kusserow on Glassdoor.com. Paul B. Kusserow has an approval rating of 79% among the company's employees. 60.0% of employees surveyed would recommend working at Amedisys to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Adobe (ADBE), Intel (INTC), QUALCOMM (QCOM), Broadcom (AVGO), Cisco Systems (CSCO) and Home Depot (HD).

Amedisys' stock is owned by a number of institutional and retail investors. Top institutional investors include Pentwater Capital Management LP (3.51%), Alpine Associates Management Inc. (3.17%), Wellington Management Group LLP (3.01%), Mackenzie Financial Corp (2.88%), Westchester Capital Management LLC (2.61%) and Van Lanschot Kempen Investment Management N.V. (1.28%). Insiders that own company stock include Bruce D Perkins, Christopher Gerard, David L Kemmerly, David L Kemmerly, Denise M Bohnert, Michael Paul North, Richard A Lechleiter and Scott G Ginn.
View institutional ownership trends.

Shares of AMED stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.